Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma

Francesco Massari, Chiara Ciccarese, Antonio Bentito Porcaro, Stefano Ferrero, Giacomo Gazzano, Walter Artibani, Alessandra Modena, Emilio Bria, Teodoro Sava, Anna Caliò, Giacomo Novara, Vincenzo Ficarra, Marco Chilosi, Guido Martignoni, Silvano Bosari, Liang Cheng, Giampaolo Tortora, Matteo Brunelli

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We sought to evaluate the expression of HSP27 and HSP90 chaperones in renal cell carcinomas as a target for cancer therapeutics. A total of 127 clear cell renal cell carcinomas stratified according to the Mayo Clinic SSIGN (size, staging, grading, and necrosis) risk groups (good, 1; poor, 5) and 20 cases with metastases, were available. Immunostaining for both HSP27 and HSP90 was performed on tissue microarrays. Results were detailed per scorable arrays per SSIGN risk groups. Immunolabelling for HSP90 and HSP27 was seen in 109 of 127 (86%) and 114 of 127 (89%) cases, respectively. HSP90 scored 4.9 in 32 cases risked SSIGN 1, 3.5 in 41 cases SSIGN 2, 4.8 in 11 cases SSIGN 3, 4.2 in 22 cases SSIGN 4, and 5.0 in three cases SSIGN 5. HSP27 scored 4.6 in 33 risked SSIGN 1, 3.1 in 43 SSIGN 2, 2.6 in 11 SSIGN 3, 3.6 in 24 SSIGN 4, and 2.7 in three SSIGN 5. Metastases ranged from 2.9-5.0. A trend of increasing value for HSP90 was observed when comparing SSIGN 1-2 versus SSIGN 3-5 risk groups (4.2 versus 4.6 mean values; p=0.06); no difference has been observed for HSP27 (3.8 to 3.9; p=0.08). A score modulation of HSPs is observed in renal cell carcinoma and may affect the efficacy of targeted therapy.

Original languageEnglish (US)
Pages (from-to)523-526
Number of pages4
JournalPathology
Volume46
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Renal Cell Carcinoma
Necrosis
Neoplasm Metastasis

Keywords

  • Clear cell renal cell carcinoma
  • Heat shock proteins
  • HSP27
  • HSP90
  • Targeted therapy

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Massari, F., Ciccarese, C., Porcaro, A. B., Ferrero, S., Gazzano, G., Artibani, W., ... Brunelli, M. (2014). Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. Pathology, 46(6), 523-526. https://doi.org/10.1097/PAT.0000000000000150

Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. / Massari, Francesco; Ciccarese, Chiara; Porcaro, Antonio Bentito; Ferrero, Stefano; Gazzano, Giacomo; Artibani, Walter; Modena, Alessandra; Bria, Emilio; Sava, Teodoro; Caliò, Anna; Novara, Giacomo; Ficarra, Vincenzo; Chilosi, Marco; Martignoni, Guido; Bosari, Silvano; Cheng, Liang; Tortora, Giampaolo; Brunelli, Matteo.

In: Pathology, Vol. 46, No. 6, 2014, p. 523-526.

Research output: Contribution to journalArticle

Massari, F, Ciccarese, C, Porcaro, AB, Ferrero, S, Gazzano, G, Artibani, W, Modena, A, Bria, E, Sava, T, Caliò, A, Novara, G, Ficarra, V, Chilosi, M, Martignoni, G, Bosari, S, Cheng, L, Tortora, G & Brunelli, M 2014, 'Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma', Pathology, vol. 46, no. 6, pp. 523-526. https://doi.org/10.1097/PAT.0000000000000150
Massari F, Ciccarese C, Porcaro AB, Ferrero S, Gazzano G, Artibani W et al. Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. Pathology. 2014;46(6):523-526. https://doi.org/10.1097/PAT.0000000000000150
Massari, Francesco ; Ciccarese, Chiara ; Porcaro, Antonio Bentito ; Ferrero, Stefano ; Gazzano, Giacomo ; Artibani, Walter ; Modena, Alessandra ; Bria, Emilio ; Sava, Teodoro ; Caliò, Anna ; Novara, Giacomo ; Ficarra, Vincenzo ; Chilosi, Marco ; Martignoni, Guido ; Bosari, Silvano ; Cheng, Liang ; Tortora, Giampaolo ; Brunelli, Matteo. / Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma. In: Pathology. 2014 ; Vol. 46, No. 6. pp. 523-526.
@article{42e2a0fdeb6a4062a5cab9e0f72c7782,
title = "Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma",
abstract = "We sought to evaluate the expression of HSP27 and HSP90 chaperones in renal cell carcinomas as a target for cancer therapeutics. A total of 127 clear cell renal cell carcinomas stratified according to the Mayo Clinic SSIGN (size, staging, grading, and necrosis) risk groups (good, 1; poor, 5) and 20 cases with metastases, were available. Immunostaining for both HSP27 and HSP90 was performed on tissue microarrays. Results were detailed per scorable arrays per SSIGN risk groups. Immunolabelling for HSP90 and HSP27 was seen in 109 of 127 (86{\%}) and 114 of 127 (89{\%}) cases, respectively. HSP90 scored 4.9 in 32 cases risked SSIGN 1, 3.5 in 41 cases SSIGN 2, 4.8 in 11 cases SSIGN 3, 4.2 in 22 cases SSIGN 4, and 5.0 in three cases SSIGN 5. HSP27 scored 4.6 in 33 risked SSIGN 1, 3.1 in 43 SSIGN 2, 2.6 in 11 SSIGN 3, 3.6 in 24 SSIGN 4, and 2.7 in three SSIGN 5. Metastases ranged from 2.9-5.0. A trend of increasing value for HSP90 was observed when comparing SSIGN 1-2 versus SSIGN 3-5 risk groups (4.2 versus 4.6 mean values; p=0.06); no difference has been observed for HSP27 (3.8 to 3.9; p=0.08). A score modulation of HSPs is observed in renal cell carcinoma and may affect the efficacy of targeted therapy.",
keywords = "Clear cell renal cell carcinoma, Heat shock proteins, HSP27, HSP90, Targeted therapy",
author = "Francesco Massari and Chiara Ciccarese and Porcaro, {Antonio Bentito} and Stefano Ferrero and Giacomo Gazzano and Walter Artibani and Alessandra Modena and Emilio Bria and Teodoro Sava and Anna Cali{\`o} and Giacomo Novara and Vincenzo Ficarra and Marco Chilosi and Guido Martignoni and Silvano Bosari and Liang Cheng and Giampaolo Tortora and Matteo Brunelli",
year = "2014",
doi = "10.1097/PAT.0000000000000150",
language = "English (US)",
volume = "46",
pages = "523--526",
journal = "Pathology",
issn = "0031-3025",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma

AU - Massari, Francesco

AU - Ciccarese, Chiara

AU - Porcaro, Antonio Bentito

AU - Ferrero, Stefano

AU - Gazzano, Giacomo

AU - Artibani, Walter

AU - Modena, Alessandra

AU - Bria, Emilio

AU - Sava, Teodoro

AU - Caliò, Anna

AU - Novara, Giacomo

AU - Ficarra, Vincenzo

AU - Chilosi, Marco

AU - Martignoni, Guido

AU - Bosari, Silvano

AU - Cheng, Liang

AU - Tortora, Giampaolo

AU - Brunelli, Matteo

PY - 2014

Y1 - 2014

N2 - We sought to evaluate the expression of HSP27 and HSP90 chaperones in renal cell carcinomas as a target for cancer therapeutics. A total of 127 clear cell renal cell carcinomas stratified according to the Mayo Clinic SSIGN (size, staging, grading, and necrosis) risk groups (good, 1; poor, 5) and 20 cases with metastases, were available. Immunostaining for both HSP27 and HSP90 was performed on tissue microarrays. Results were detailed per scorable arrays per SSIGN risk groups. Immunolabelling for HSP90 and HSP27 was seen in 109 of 127 (86%) and 114 of 127 (89%) cases, respectively. HSP90 scored 4.9 in 32 cases risked SSIGN 1, 3.5 in 41 cases SSIGN 2, 4.8 in 11 cases SSIGN 3, 4.2 in 22 cases SSIGN 4, and 5.0 in three cases SSIGN 5. HSP27 scored 4.6 in 33 risked SSIGN 1, 3.1 in 43 SSIGN 2, 2.6 in 11 SSIGN 3, 3.6 in 24 SSIGN 4, and 2.7 in three SSIGN 5. Metastases ranged from 2.9-5.0. A trend of increasing value for HSP90 was observed when comparing SSIGN 1-2 versus SSIGN 3-5 risk groups (4.2 versus 4.6 mean values; p=0.06); no difference has been observed for HSP27 (3.8 to 3.9; p=0.08). A score modulation of HSPs is observed in renal cell carcinoma and may affect the efficacy of targeted therapy.

AB - We sought to evaluate the expression of HSP27 and HSP90 chaperones in renal cell carcinomas as a target for cancer therapeutics. A total of 127 clear cell renal cell carcinomas stratified according to the Mayo Clinic SSIGN (size, staging, grading, and necrosis) risk groups (good, 1; poor, 5) and 20 cases with metastases, were available. Immunostaining for both HSP27 and HSP90 was performed on tissue microarrays. Results were detailed per scorable arrays per SSIGN risk groups. Immunolabelling for HSP90 and HSP27 was seen in 109 of 127 (86%) and 114 of 127 (89%) cases, respectively. HSP90 scored 4.9 in 32 cases risked SSIGN 1, 3.5 in 41 cases SSIGN 2, 4.8 in 11 cases SSIGN 3, 4.2 in 22 cases SSIGN 4, and 5.0 in three cases SSIGN 5. HSP27 scored 4.6 in 33 risked SSIGN 1, 3.1 in 43 SSIGN 2, 2.6 in 11 SSIGN 3, 3.6 in 24 SSIGN 4, and 2.7 in three SSIGN 5. Metastases ranged from 2.9-5.0. A trend of increasing value for HSP90 was observed when comparing SSIGN 1-2 versus SSIGN 3-5 risk groups (4.2 versus 4.6 mean values; p=0.06); no difference has been observed for HSP27 (3.8 to 3.9; p=0.08). A score modulation of HSPs is observed in renal cell carcinoma and may affect the efficacy of targeted therapy.

KW - Clear cell renal cell carcinoma

KW - Heat shock proteins

KW - HSP27

KW - HSP90

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84961290050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961290050&partnerID=8YFLogxK

U2 - 10.1097/PAT.0000000000000150

DO - 10.1097/PAT.0000000000000150

M3 - Article

VL - 46

SP - 523

EP - 526

JO - Pathology

JF - Pathology

SN - 0031-3025

IS - 6

ER -